TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Antigenics May Finally Be Back on the Uptick VFC submits: Shares of Antigenics (AGEN) have traded with increased volatility during Monday's and early Tuesday's trading sessions which could be an indicator that news is pending.The company's Russian launch of its kidney cancer vaccine Oncophage is set to take place in the fourth quarter of this year, according to previous announcements by the company, and news of Russian government reimbursement should hit the wires before that time.Complete Story » seekingalpha.com |
BioMed News Bytes: NicOx, Allos, Pressure BioSciences, YM BioSciences Mike Havrilla submits:On 5/19/09, NicOx (NICXF.PK) announced that quality of life and utility results from its first Phase 3 clinical trial for naproxcinod were presented at the International Society For Pharmacoeconomics and Outcomes Research Annual International Meeting in Orlando, FL. Naproxcinod is a novel type of anti-inflammatory agent, which completed a Phase 3 clinical program last year in patients with osteoarthritis. The drug is designed to have an improved side effect profile (including a neutral effect on blood pressure) as compared to a standard dose of the widely used NSAID drug naproxen. Naproxcinod has completed three pivotal Phase 3 studies with positive results. On 9/25/09, NicOx submitted a NDA for naproxcinod to the FDA for an estimated decision date of 7/25/10 for a standard, 10-month review.Complete Story » seekingalpha.com |
AGA Medical Gains Slightly in Debut Medical-device maker AGA Medical Holdings gained almost 1% in its IPO after slashing the price of its deal and increasing the number of shares sold by its founder. online.wsj.com |
20 Medical Advances to Be Thankful For Despite anxieties about new health risks, life is getting demonstrably better for many people in the U.S. and abroad. online.wsj.com |
Biotech Gears Up for JP Morgan Conference The Burrill Report submits: The biotechnology industry is gearing up for the annual JPMorgan Healthcare conference, the key annual meeting that kicks off the New Year for the industry. Last year the dismal economy cast a long shadow at the normally upbeat conference, but much has changed since then. We spoke to Adam Feuerstein, Senior Columnist for TheStreet.com, about how far the industry has come during the past year, what he’ll be looking for at this year’s conference and whether or not biotech executives will be in a celebratory mood once again.Complete Story » seekingalpha.com |